AgingResearch.NewsJoin free

AAV2-SIRT6

AAV2-SIRT6 has been studied in 1 paper since 2024: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Apr 24, 2024: “Sirt6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma”.

Intervention

1 paper studies it1 findingUpdated

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: Cancer Prevention and Research Institute of Texas and 6 more
  • Animals1

What did studies of AAV2-SIRT6 find?

1

Studies of AAV2-SIRT6 measured 1 outcome; the most studied are RGC degeneration (1 study).

RGC degeneration

downin mice1

1 study

  1. AAV2-SIRT6 decreases RGC degeneration in mice.

    “therapeutically targeting Sirt6 with pharmacological activator or AAV2-mediated gene delivery ameliorated high IOP-induced RGC degeneration”

    Animalsin high IOP mouse model

    Sirt6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma

    Molecular therapy : the journal of the American Society of Gene Therapy

Latest

Related